Trade IGM Biosciences Inc - IGMS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 50.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 1.35 |
| Open | 1.32 |
| 1-Year Change | -83.31% |
| Day's Range | 1.27 - 1.34 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 25, 2025 | 1.29 | -0.03 | -2.27% | 1.32 | 1.34 | 1.27 |
| Apr 24, 2025 | 1.35 | 0.02 | 1.50% | 1.33 | 1.40 | 1.28 |
| Apr 23, 2025 | 1.35 | -0.03 | -2.17% | 1.38 | 1.43 | 1.26 |
| Apr 22, 2025 | 1.42 | 0.20 | 16.39% | 1.22 | 1.43 | 1.22 |
| Apr 21, 2025 | 1.25 | 0.06 | 5.04% | 1.19 | 1.29 | 1.19 |
| Apr 17, 2025 | 1.19 | 0.08 | 7.21% | 1.11 | 1.21 | 1.11 |
| Apr 16, 2025 | 1.16 | -0.03 | -2.52% | 1.19 | 1.24 | 1.12 |
| Apr 15, 2025 | 1.23 | 0.08 | 6.96% | 1.15 | 1.26 | 1.15 |
| Apr 14, 2025 | 1.16 | 0.01 | 0.87% | 1.15 | 1.18 | 1.10 |
| Apr 11, 2025 | 1.16 | 0.17 | 17.17% | 0.99 | 1.17 | 0.99 |
| Apr 10, 2025 | 1.02 | -0.01 | -0.97% | 1.03 | 1.03 | 0.96 |
| Apr 9, 2025 | 1.02 | 0.05 | 5.15% | 0.97 | 1.06 | 0.88 |
| Apr 8, 2025 | 0.98 | -0.09 | -8.41% | 1.07 | 1.09 | 0.97 |
| Apr 7, 2025 | 1.08 | 0.03 | 2.86% | 1.05 | 1.16 | 0.97 |
| Apr 4, 2025 | 1.10 | 0.00 | 0.00% | 1.10 | 1.12 | 1.07 |
| Apr 3, 2025 | 1.13 | 0.01 | 0.89% | 1.12 | 1.17 | 1.10 |
| Apr 2, 2025 | 1.19 | 0.10 | 9.17% | 1.09 | 1.19 | 1.09 |
| Apr 1, 2025 | 1.11 | -0.02 | -1.77% | 1.13 | 1.17 | 1.08 |
| Mar 31, 2025 | 1.12 | -0.01 | -0.88% | 1.13 | 1.15 | 1.09 |
| Mar 28, 2025 | 1.21 | -0.05 | -3.97% | 1.26 | 1.26 | 1.19 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 20
- 100
- 500
- 1000
- 10000
IGM Biosciences, Inc. Company profile
About IGM Biosciences Inc
IGM Biosciences, Inc. is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of multiple diseases. It has developed an IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. Its lead product candidate, IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, is in an ongoing Phase I clinical trial for the treatment of relapsed/refractory B-cell non-Hodgkin’s lymphoma (NHL) patients. Its second product candidate, IGM-8444, is an IgM antibody targeting Death Receptor 5 (DR5) proteins, which is for the treatment of patients with solid and hematologic malignancies. The Company’s pipeline also includes IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.
Financial summary
BRIEF: For the nine months ended 30 September 2021, IGM Biosciences Inc revenues was not reported. Net loss increased from $56.7M to $114.5M. Higher net loss reflects Research and development - Bala increase of 89% to $80.3M (expense), General and administrative - Balanc increase of 67% to $17.1M (expense), Stock-based Compensation in SGA increase from $2.9M to $9.7M (expense).
| Industry: | Bio Therapeutic Drugs |
325 E Middlefield Rd
MOUNTAIN VIEW
CALIFORNIA 94043-4003
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com